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Background: Many preschool children develop recurrent respiratory tract infections (RRI). Strategies to prevent
RRI include the use of immunomodulators as pidotimod or probiotics, but there is limited evidence of their
efficacy on clinical features or on urine metabolic profile.
Objective: To evaluate whether pidotimod and/or bifidobacteria can reduce RRI morbidity and influence the
urine metabolic profile in preschool children.
Materials and methods: Children aged 3–6 years with RRI were enrolled in a four-arm, exploratory, prospective,
randomized, double-blinded, placebo-controlled trial. Patients were randomly assigned to receive pidotimod plus
bifidobacteria, pidotimod plus placebo, bifidobacteria plus placebo or double placebo for the first 10 days of each
month over 4 consecutive months. Respiratory symptoms and infections were recorded with a daily diary by
parents during the study. Metabolomic analyses on urine samples collected before and after treatment were
performed.
Results: Compared to placebo, children receiving pidotimod, alone or with bifidobacteria, had more symptom-
free days (69 versus 44, p=0.003; and 65 versus 44, p=0.02, respectively) and a lower percentage of days with
common cold (17% versus 37%, p=0.005; and 15% versus 37%, p=0.004, respectively). The metabolomic
analysis showed that children treated with Pidotimod (alone or in combination with bifidobacteria) present,
respect to children treated with placebo, a biochemical profile characterized by compounds related to the
pathway of steroids hormones, hippuric acid and tryptophan. No significant difference in the metabolic profile
was found between children receiving bifidobacteria alone and controls.
Conclusions: Preschool children with RRI treated with pidotimod have better clinical outcomes and a different
urine metabolomic profile than subjects receiving placebo. Further investigations are needed to clarify the
connection between pidotimod and gut microbiome.
1. Introduction
Recurrent respiratory infections (RRI) represent a widespread
condition that largely contributes to pediatric morbidity and has also
considerable economic and social impact [1]. In patients with RRI an-
tibiotics may be overused, and increased bacterial resistance has
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become an important matter of concern worldwide [2]. Interestingly,
RRI in the first years of life is a possible co-factor in the development of
chronic lung disorders, namely asthma and chronic obstructive pul-
monary disease [3]. In view of the early impact of RRI on human health
and of its social burden, limiting the condition in the pediatric popu-
lation shows remarkable promise to prevent chronic lung diseases in
adulthood.
Pidotimod is an immunostimulant with proved clinical efficacy in
RRI prevention both in open [4–7] or randomized controlled trials
(RCTs) [8–10], albeit the mechanism of action has been elucidated only
in part [11–13]. A recent study of children with RRI demonstrated that
pidotimod can partially “restore” the altered metabolic profile found in
these children, even though some metabolites originating from the
microbiota were still partially altered after treatment [14]. Based upon
these findings, we hypothesized a potential interactive effect of im-
munostimulants and probiotics on preventing RRI in children and also
wondered if they had any influence on the metabolomic profiling. Also
probiotics were suggested to have a preventive effect on respiratory
infections, but evidences are quite limited [15]. Hence, we conducted
an exploratory prospective RCT to determine if the treatment with pi-
dotimod and/or bifidobacteria can reduce the morbidity of RRI and
modify the urine metabolomic profile of preschool children with RRI.
2. Methods
2.1. Study design and participants
The exploratory study, designed as a four-arm, prospective, rando-
mized, double-blinded, placebo-controlled clinical trial, was conducted
at the Department of Translational Medical Sciences, Section of
Pediatrics, Federico II University, Naples, Italy. We recruited all 3-to-6
year-old children with RRI consecutively seen at the Pediatric
Pulmonology Unit, Federico II University, and at the office of 22 pri-
mary care pediatricians uniformly distributed across the urban and
suburban areas of the city of Naples. Metabolomic analysis was per-
formed at the Department of Women's and Children's Health, Mass
Spectrometry Laboratory, Fondazione Istituto di Ricerca Pediatrica
Città della Speranza, University of Padua, Italy.
Inclusion criteria were: (a) age 3–6 years; (b) attendance to nursery
school/kindergarten; (c) diagnosis of RRI [16]. Exclusion criteria were:
(a) not meeting inclusion criteria; (b) presence of chronic medical
conditions, including cardiovascular or any systemic disease, neurolo-
gical disorders, primary or secondary immunodeficiency, cystic fibrosis,
or primary ciliary dyskinesia; (c) Down syndrome; (d) airways mal-
formation; (e) recurrent wheezing [17]; (f) administration of im-
munomodulators or systemic steroids in the previous 4 weeks; (g)
current acute respiratory and/or any other infection requiring hospital
admission.
We generated a randomization list and subsequently balanced be-
tween treatments. Patients were randomly assigned to one of the 4 arms
to receive active medications or placebos as follows:
− group A (pidotimod + bifidobacteria group): pidotimod as liquid
suspension in 400 mg vial (one vial/day) + bifidobacteria mixture
(B longum BB536, 3 × 109 CFU; B infantis M-63, 1x109 105 CFU; B
breve M-16 V, 1x109 106 CFU) as powder in 3 g sachet (one sachet/
day);
− group B (pidotimod group): pidotimod as liquid suspension in
400 mg vial (one vial/day) + identical-looking and -tasting placebo
of bifidobacteria mixture sachet (one sachet/day);
− group C (bifidobacteria group): identical-looking and -tasting pi-
dotimod placebo as liquid suspension in a vial (one vial/day) + bi-
fidobacteria mixture (B longum BB536, 3 × 109 CFU; B infantis M-
63, 1x109 105 CFU; B breve M-16 V, 1x109 106 CFU) as powder in
3 g sachet (one sachet/day);
− group D (placebo group): identical-looking and -tasting pidotimod
placebo as liquid suspension in a vial (one vial/day) + identical-
looking and -tasting placebo of bifidobacteria mixture sachet (one
sachet/day).
The study protocol required that patients received oral active
medications and/or placebos for the first 10 days of each month for 4
months, and were subsequently followed-up for an additional period of
2 months. The compounds were provided in identical vials and sachets,
and the placebo and active drugs did not differ in smell or color. Neither
study personnel nor parents were aware of the nature of the product.
The study had primary and secondary endpoints. The primary
clinical endpoint included the number of symptom-free days and the
number of days with common cold per participant. The secondary
endpoint was to determine any change in the urine metabolic profile
before and after treatment.
This RCT was conducted during 2 autumn seasons, over the same
three-months periods in 2 consecutive years. In the first study period
(October, November, December 2015), we enrolled patients with the
aim of seeking out any clinically evident effect of the treatment with
pidotimod and/or bifidobacteria. In the second study period (October,
November, December 2016), we enrolled another cohort of patients
who satisfied the same study inclusion criteria with the dual aim of
evaluating the clinical effects of the treatments and of characterizing
the metabolic profiles of patients' urine samples by mass-spectrometry-
based metabolomics, in order to fulfill the secondary aim of the study,
i.e. to determine whether there is any difference in the urine metabolic
profile before and after treatment among the 4 groups. The study
started on October 2015 and the follow-up of the last child was com-
pleted in May 2017. The schedule of the 4 visits (at the recruitment and
after 8, 16, and 24 weeks) and data collection points are summarized in
Table 1. The daily diary included questions about the occurrence of
body temperature superior to 37 °C, cough, sore throat, common cold,
ear pain, hoarseness, and/or a physician-made diagnosis of tracheo-
bronchitis or pneumonia. Any additional therapy was allowed with the
exclusion of immunomodulators, probiotics and systemic steroids. Over
the entire study, patients were monitored by telephone calls every
month to remind the study procedure to the parents and monitor par-
ticipants’ adherence to the protocol. Personal history was collected for
every patient and none of the children enrolled followed special diets or
an elimination diet. We therefore assumed that children considered in
the study had common diet habits and common lifestyles according to
their age.
All study procedures were performed in accordance with the de-
claration of Helsinki and approved by the Ethical Committee, Federico
II University, Naples (protocol no. 173/2015). Study participants and
parents were informed about the study procedure in detail and written
informed consent was obtained.
Table 1
Summary of visits and measurements for the trial.
Visit 1 Visit 2 Visit 3 Visit 4
T0 8 weeks
after
16 weeks
after
24 weeks
after
Written informed consent ✓
Demographics ✓
Inclusion/exclusion criteria
verification
✓
Randomization ✓
Medications/placebos delivery/
collection
✓ ✓ ✓
Adverse events registration ✓ ✓ ✓
Daily diary delivery/collection/
supervision
✓ ✓ ✓ ✓
Urine for metabolomics analysis ✓ ✓
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2.2. Untargeted metabolomics analysis
In the second study period (October, November, December 2016),
all children who had been recruited underwent the same clinical pro-
tocol of the first study period and, in addition, were asked to collect at
least 6mL of urine for the metabolomic analysis at visit 1, before any
active drug or placebo administration, and at visit 3 (4 months after
enrollment), respectively. The urine samples were immediately stored
at −80 °C until metabolomic analysis was performed. The urine sam-
ples were thawed at room temperature, stirred for 30 s in a vortex
mixer, and then centrifuged at 6000 g for 10min to remove the sedi-
ment present in the urine. We transferred 100 μL of the supernatant into
a test tube and added 400 μl of H2O containing 0.1% formic acid (FA) to
obtain a 1:5 dilution. Each diluted sample was transferred into a glass
vial, placed in the autosampler and kept at 5 °C.
2.3. Ultra-performance liquid chromatography (UPLC)-Mass spectrometry
(MS) analysis
All urine samples were analyzed using a Waters Acquity UPLC
system coupled to a Waters Q-TOF Synapt G2 mass spectrometer
(Waters Corp., Milford, MA, USA). We injected 5 μL of each diluted
sample into a Waters Acquity HSS T3 2.1×100mm column packed
with 1.7 μm beads kept at 50 °C. The mobile phase for elution was
composed of solvent A (H2O, 0.1% FA) and solvent B [methanol/acet-
onitrile (MeOH/CH3CN) 90:10/0.1% FA, v/v]. The gradient elution
started with 5% B isocratically for 1 min, followed by a linear gradient
to 30% B in 2.5 min, then to 95% B in other 2.5 min. The composition
was kept at 95% B for 2 min to clean the column and then changed to
5% B to equilibrate to the initial conditions for 3 min, for a total run
time of 11 min. The flow rate was 500 μL/min. The electrospray source
of Q-TOF was operated in positive (ESI+) and negative (ESI-) ioniza-
tion mode with a capillary voltage set at 3 kV and 1.5 kV respectively.
Data were collected in continuum mode, with a mass scan range of
20–1200 m/z, a resolution of 20.000. A leucine-enkephalin solution was
used as lock-mass. All UPLC–ESI-TOF-MS operations were controlled
with MassLynx 4.1 (Waters, Milford, MA, USA).
In order to assess the reproducibility and accuracy during the ana-
lysis and to evaluate the metabolite content of the samples, Quality
Control samples (QC) and Standards Solution Samples (Mix) were used.
The QCs were prepared mixing together an aliquot of each sample and
then diluting the mixture to 1:2, 1:3 and 1:5 (H2O, 0.1% FA), obtaining
three type of QCs. The standards solution consisted of a mix of nine
compounds, whereof the exact mass and retention time are known.
The QCs and Mix samples were injected at regular intervals during
the sequence, together with blank samples (H2O, 0.1% FA), to de-
termine specific ions from the mobile phase and to find out any con-
taminants. The analysis was performed in triplicate. The samples were
injected randomly to prevent any spurious classification deriving from
the samples position in the sequence.
2.4. Data pre-processing and pre-treatment
UPLC-MS data were processed by the software Progenesis (Waters)
and two data sets were generated, one for the positive-ionization mode
(POS data set) and the other for the negative-ionization mode (NEG
data set). The parameters used for data extraction were optimized
through the preliminary analysis processing of the QC samples. As a
result, the so called Rt_mass variables (where Rt is the retention time
and mass is the mass to charge ratio m/z of the chemical compound)
were generated.
Variables with a coefficient of variation in the QCs greater than 15%
or a ratio of the 5th percentile measured in the QCs and the 95th per-
centile measured in the blank samples less than 5 were excluded.
Missing data were imputed by generating a random number between
zero and the minimum value measured for the variable. For each type
of QCs, linear regression models were generated to estimate the vari-
able level as a function of the run order. Then, the level of each variable
in the samples was calculated regressing the intensity of the variable
obtained by data extraction on the linear model built using the level of
the variable in the three QCs estimated at the same run order of the
sample as response and the dilution factors as independent variables.
After probabilistic quotient normalization [18], median was applied
to each variable of the triplicates. The differences between the urine
metabolite content after 16 weeks of treatment (Visit 3) and at the
baseline (Visit 1) were used to obtained the sample representation
useful for data analysis.
2.5. Data analysis
In the analysis of the primary outcome, homogeneity of baseline
values was carried out by using appropriate statistical test (ANOVA or
Chi Square test). Inferential statistics to compare treatment groups was
performed using ANOVA followed by post–hoc Dunnett's test multiple
comparison versus placebo. Significance level was set to α=0.05.
In the analysis of the secondary outcome, multivariate data analysis
based on projection methods and univariate data analysis were applied
to investigate the differences in the metabolomic profile of the 4 groups
of interest. Specifically, the group D (i.e. placebo) was considered as a
control group and the other three groups were independently compared
to it. Exploratory data analysis was performed by Principal Component
Analysis (PCA), whereas post-transformation of Projection to Latent
Structures Discriminant Analysis (ptPLS2-DA) [19] was applied to
evaluate if differences exist between the group under investigation and
group D. The predictive performance of the ptPLS2-DA models was
estimated by means of the Area Under the Receiver Operating Char-
acteristic curve (AUC) of the outcomes of the predictions during 5-fold
cross-validation (i.e. AUCCV). Permutation test on the group response
was performed to avoid over-fitting. Since multivariate data analysis
explores the correlation structure of the collected data, while univariate
data analysis investigates the properties of single variables, we per-
formed also univariate data analysis by t-test and ROC curve analysis
with False Discovery Rate in order to complete the results of the mul-
tivariate data analysis. We selected the variables with q-value less than
0.05 for both t-test and AUC. We performed PCA, ptPLS2-DA, t-test and
ROC analysis with False Discovery Rate by the R 3.3.2 platform (R
Foundation for Statistical Computing).
The main available metabolomic databases (Human Metabolome
DataBase and METLIN) were searched to annotate the selected vari-
ables characterizing each group. We considered a mass tolerance of
10 ppm.
3. Results
3.1. Clinical results
A total of 55 children were enrolled (30 in the first and 25 in the
second study period), were randomized to the 4 groups, and completed
the study (Table 2).
No significant differences in age, gender, body weight, height, and
number of upper or lower respiratory tract infections in the previous
year were found among the groups. Twenty-five out of 55 children
underwent the metabolomic analysis of urine samples. When compared
to the data from the 55 patients, no significant differences in gender,
age, weight and height were found in this subgroup (Table S1 in Sup-
plementary material). In Table 3 we report the results of the whole 6-
month study period for the 55 enrolled children.
Compared to group D (“placebo group”), groups A (“pido-
timod + bifidobacteria group”) and B (“pidotimod group”) showed a
significantly higher proportion of symptom-free days (69 versus 44,
p=0.003; and 65 versus 44, p=0.02, respectively) and a lower per-
centage of days with common cold (17% versus 37%, p=0.005; and
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15% versus 37%, p=0.004, respectively). No differences in treatment
adherence were found among the groups. All treatments were well
tolerated and no adverse events associated to treatments were reported
in any patient. No significant differences in the proportion of children
treated with antibiotics and in the number of days of therapy were
found among the groups. Similar clinical results were found in the
subset of 25 children enrolled in the second study period (Table S2 in
Supplementary material).
3.2. Metabolomic analysis
The urine metabolomic analysis was performed in 25 patients en-
rolled in the second study period. The UPLC-MS analysis of the urine
samples led to the generation of two data sets: the POS data set, ob-
tained in positive ionization mode including 1329 Rt_mass variables,
and the NEG data set, in negative ionization mode comprising 1346
Rt_mass variables. A preliminary exploratory data analysis was per-
formed by PCA on each data set to identify outliers and specific patterns
in the data collected. No outliers were detected on the basis of the
DModX test and Hotelling's T2 test (α=0.05) performed on the PCA
models of each group. Moreover, no differences in the metabolic profile
were observed among the 4 groups at the baseline.
3.2.1. Group D (“placebo group”) versus group C (“bifidobacteria group”)
No significant differences were highlighted by multi- and univariate
data analysis for both the NEG data set and the POS data set.
Specifically, ptPLS2-DA models did not pass the permutation test on the
group response and q-values resulted to be greater than 0.20 for all the
variables.
3.2.2. Group D (“placebo group”) versus group B (“pidotimod group”)
Significant differences between group D and group B were detected
by multi- and univariate data analysis. ptPLS2-DA models (mean cen-
tering and Pareto scaling, 1 predictive latent variables) showed
AUCCV= 0.85 (p-value=0.041) for the POS data set and
AUCCV= 0.81 (p-value=0.049) for the NEG data set. The score bar
plot of the model for the POS data set is reported in Fig. 1.
A similar plot was obtained for the NEG data set (data not shown).
We selected 384 variables by univariate data analysis, 357 from the
POS data set and 27 from the NEG data set. Variable annotation is re-
ported in Table S3 in Supplementary material.
3.2.3. Group D (“placebo group”) versus group A
(“pidotimod + bifidobacteria group”)
Significant differences between group D and group A were high-
lighted by multi- and univariate data analysis. ptPLS2-DA models
(mean centering and Pareto scaling, 1 predictive latent variables)
showed AUCCV=0.98 (p-value=0.016) for the POS data set and
AUCCV= 0.99 (p-value=0.002) for the NEG data set. The score bar
plot of the model for the POS data set is reported in Fig. 2.
A similar plot was obtained for the NEG data set (data not shown).
We selected 647 variables by univariate data analysis, 356 from the
POS data set and 291 from the NEG data set. Variable annotation is
reported in Table S4 in Supplementary material.
The results of data analysis are summarized in the Shared and
Unique Structure plot (SUS-plot) showed in Fig. 3 [20], where the
predictive correlation loadings of each variable calculated for the
ptPLS2-DA model distinguishing group D and group A and for the
model separating group D and group B are reported in the same plot.
Many variables are close to the diagonal of the plot, and therefore it
can be assumed that the variables distinguishing group D from group A
likely separate also group D from group B (“shared variables”), this
suggesting that the effect might be attributed to the presence of pido-
timod. Among them, we found variables that could be ascribable to
some metabolites of steroid hormones or those deriving from the vi-
tamin B pathway, and some amino acid derivatives. On the other hand,Ta
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some variables lie on the extreme regions of the horizontal/vertical axis
(close to −0.8 or 0.8) suggesting that some metabolites can be related
to interactive effects of pidotimod and bifidobacteria. Among them, we
annotated variables that could be ascribable to a derivative of hippuric
acid (Methylhippuric acid) and to tryptophan metabolites (L-
Kynurenine), to deoxycholic acid 3-glucuronide (a metabolite of bile
acid), to oxoglutaric acid, to metabolites of tryptamine (trace amines)
and to some metabolites belonging to the ubiquinone family.
4. Discussion
This RCT enrolled preschool children who attended nursery school/
kindergarten and had RRI, a condition representing an early life
troublesome event typically cared for in primary care settings. We de-
monstrated that pidotimod, alone or combined with bifidobacteria, is
effective in significantly decreasing the days of illness along with re-
ducing symptoms due to common cold, while there were no significant
differences when patients treated with bifidobacteria alone were com-
pared to the placebo group.
In the last decades several studies on the immunostimulant pido-
timod have been published to prove its clinical efficacy in pediatric RRI
[4–6,8,9,21], but only few of these were RCTs. Interestingly, one of the
first document reviewing the pediatric literature encouraged national
health authorities to conduct large, multicentre, double-blind, placebo-
controlled trials on the effects of pidotimod [22]. A recent clinical RCT
found that 3-year-old children receiving pidotimod had less than 44%
Table 3
Clinical outcomes in the 55 children with recurrent respiratory infections.
Group A
(Pidotimod + bifidobacteria)
(n = 13)
Group B
(Pidotimod + placebo of bifidobacteria)
(n = 13)
Group C
(Placebo of pidotimod + bifidobacteria)
(n = 13)
Group D
(Double placebo)
(n= 16)
Number of URTI 39 53 64 58
Number of LRTI 2 4 1 6
Number of days with URTI 21 (0-66)a 25 (0-72)a 37 (7-72)a 32 (0-82)a
Number of days with LRTI 7 (7-7)a 5 (2-7)a 10 (10-10)a 10 (4-17)a
Symptom-free days (%) 65b 69c 59 44
Days with common cold (%) 15d 17e 26 37
Days with fever (%) 1 4 4 3
Days with cough (%) 21 18 27 32
Days with sore throat (%) 8 3 3 10
Days with hoarseness (%) 2 1 2 6
Days with ear pain (%) 1 1 1 1
Workdays lost by the parents (%) 2 7 5 14
Abbreviations: URTI, upper respiratory tract infections; LRTI, lower respiratory tract infections.
a Values are expressed as mean (range).
b p=0.02 versus Group D.
c p=0.003 versus Group D.
d p=0.004 versus Group D.
e p=0.005 versus Group D.
Fig. 1. Group D (“placebo group”) versus group B (“pidotimod group”): score
bar plot of the ptPLS2-DA model for the POS data set. White bars indicate
children from group D, grey bars refer to group B children. tp is the predictive
score of the model.
Fig. 2. Group D (“placebo group”) versus group A (“pidotimod + bifidobacteria
group”): score bar plot of the ptPLS2-DA model for the POS data set. White bars
indicate children from group D, black bars refer to children from group A. tp is
the predictive score of the model.
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of relative prescription of antibiotics when compared to the placebo
group [10]. Two additional studies have shown that, when adminis-
tered together with standard antibiotic treatment, pidotimod is asso-
ciated with a favorable persistent immunomodulatory effect in children
or adults with pneumonia, suggesting a decrease in the risk of early
recurrences of the episodes [7,23]. Finally, a recent meta-analysis of
trials conducted in children with RRI has demonstrated that the treat-
ment with pidotimod results in a significant decrease in the duration of
cough and fever without increasing the risk of adverse events of any
cause [24]. The findings from the current RCT confirm and extend these
results, highlighting that pidotimod significantly improves the clinical
outcome of children with RRI.
A major novel finding from the present study is provided by the
metabolomic analysis. Metabolomics is a high-dimensional biological
method that can be used for hypothesis-free biomarker discovery, ex-
amining a large number of metabolites in a given sample using spec-
troscopic techniques [25]. Statistical data analysis then enables us to
infer which metabolic information is relevant to the biological char-
acterization of a given condition. This can lead to the discovery of new
metabolites, and hitherto unknown metabolic pathways, enabling the
formulation of new pathogenetic hypotheses and novel therapeutic
targets [26]. The metabolomic analysis has been largely applied in the
field of pediatric infectious disorders [27–31]. For the first time, we
demonstrated that children with RRI receiving pidotimod have a me-
tabolomic profile of urine significantly different from the placebo
group. These differences were observed regardless children were taking
pidotimod alone (group B) or in combination with bifidobacteria (group
A), and concern steroid hormones, metabolites of vitamin B metabolism
and amino acid derivatives. Steroid hormones exert immuno-regulatory
effects both in vivo and in vitro and could represent the activation of the
hypothalamus-pituitary-adrenal axis in the interaction between neu-
roendocrine and immune systems [32]. Vitamin B mostly derives from
diet, but also bacteria can synthesize it, and recent studies have
demonstrated that human immune system can use vitamin B as a point
of difference to recognize infection through mucosal-associated in-
variant T cells in mucosal surfaces (intestine, mouth, and lungs)
[33,34]. From a clinical point of view, no differences were found be-
tween children treated with pidotimod alone and children taking pi-
dotimod plus bifidobacteria mixture, and these two groups seem to
behave in the same way. However, the metabolomic analysis revealed a
different biochemical behavior. The interaction between bifidobacteria
and pidotimod produces different metabolic changes related to a
number of products such as the bile acid metabolites, a derivative of
hippuric acid, the tryptophan metabolites, the oxoglutaric acid, the
metabolite of tryptamine and the metabolites belonging to the ubiqui-
none family. Actually, hippuric acid and bile acid metabolites are likely
associated with the microbiota composition and emerged as dis-
criminant metabolites in a recent trial of children with RRI receiving
pidotimod compared to healthy controls [14]. The findings from that
study point toward a role of the microbiota in the immune regulation,
even though we do not know how they can precisely interact and/or are
influenced by the probiotic supplementation [14].
Current metabolomic results deserve further comments. The tryp-
tophan metabolite L-Kynurenine can derive from the enteric bio-
transformation and be associated with the microbiota composition, thus
confirming the crucial role of tryptophan and its metabolites in the
balance between intestinal immune tolerance and gut microbiota
maintenance [35,36]. The metabolites of oxoglutaric acid may be re-
lated to the microbiota composition as well [37], while metabolites of
tryptamine (trace amines) may be associated with microbiome growth.
Considering the metabolites belonging to the ubiquinone family in the
context of the microbiota, a recent study based on genomic analysis,
provided further insight into the quinone biosynthesis by microorgan-
isms from the human gut microbiota [38]. Our findings cannot be at-
tributed to the bifidobacteria effect only because no differences in the
metabolomic profile were found between placebo and group C (bifi-
dobacteria group), and thus can be at least partially interpreted as the
result of the combined effect of the two agents (pidotimod plus bifido-
bacteria) on the metabolomic arrangement. Gut microbiota helps to
protect against pathogenic infections through several mechanisms, in-
cluding competition, antimicrobial peptide secretion, antibody pro-
duction, lymphoid tissue development, innate immune cell stimulation,
and T cell differentiation [39]. However, there is emerging evidence
that the role of gut microbiota on immunity extends beyond the gas-
trointestinal tract. In particular, it has been demonstrated to support
immune functions that are critical for maintaining homeostasis in the
respiratory tract against viruses and bacteria [40–45]. These findings
point toward a critical role for gut microbes in respiratory host defense,
as they provide microbial signals or determinants critical for immune
priming and shaping of the response to infections. Hence, it seems
reasonable that influencing the microflora may potentially modulate
the immune response and eventually improve individuals’ immune
status. As in our study antibiotic assumption was allowed, if needed,
and given that it is well known that antibiotics deeply affect microbiota
composition and metabolomic profile, it is theoretically possible that
this kind of treatment might have affected our results. However, no
significant differences in the proportion of children treated with anti-
biotics and in the number of days of therapy were found among the
groups, which significantly reduces the risk of bias due to this treat-
ment.
Our study has strengths and limitations. The major strength is that
this is the first prospective, randomized, double-blinded, placebo-con-
trolled trial evaluating the clinical efficacy as well as the effects on the
urine metabolomic profiling of the combined use of an im-
munostimulant and probiotics for preventing RRI in preschool children.
The inclusion criteria we set were very strict, thus avoiding as many
confounding factors as possible. Moreover, we administered a mixture
rather than a single strain of bifidobacteria. Indeed, multistrain pro-
biotics seem to be more effective than single strains [46]. Whether this
Fig. 3. SUS-plot for the POS data set: variables distinguishing group D and
group B are reported as grey inverted triangle, variables separating group D and
group A as light grey triangles, whereas black boxes indicate variables distin-
guishing both group D from group A and group D from group B. Open circles
indicate variables that did not result significant in the analysis.
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is due to synergistic interactions between strains or a consequence of
the higher probiotic dose is at present unclear.
On the other hand, as limitation of the study, we acknowledge that
our population size was small. However, the robustness of the dis-
criminant models we found was guaranteed by the conservative
thresholds we used to limit false discovery rate (q-value less than 0.05
for both t-test and AUC). Moreover, the fact that in this study children
treated with bifidobacterium mixture alone did not show variations in
the metabolomic profile versus the placebo group might be due to the
design we adopted, that included a limited period of administration of
the active medications or placebos in each group. Indeed, in previous
publications the mixture has been continuously administered for 4–6
weeks [47,48], while our population has received all the medicines
during the first 10 days of each month for 4 months in order to avoid
loss of compliance due to different administration schedule among
treatments. Thus, we cannot exclude that a prolonged treatment with
probiotics might result in significant changes in the clinical outcomes
and metabolomic findings associated with pediatric RRI. Finally, ac-
cording to this study design, we did not enroll a group of healthy
children in order to assess whether and to what extent the combined
treatment and the monotherapies can “restore”, at least in part, the
metabolic profiles found in our patients with RRI. Future RCTs on po-
pulations receiving a more prolonged probiotic treatment and including
also healthy controls are warranted to further understand the im-
munomodulatory effects of pidotimod and bifidobacteria in terms of
RRI prevention.
In conclusion, the novel finding from this study is that children with
RRI treated with pidotimod have better clinical outcomes and a dif-
ferent urine metabolomic profiling after treatment compared to subjects
receiving placebo, while patients treated only with bifidobacteria did
not show any difference in clinical outcomes and metabolomic profile
in comparison to the placebo group. Although group A (“pido-
timod + bifidobacteria group”) and B (“pidotimod group”) did not
differ from the clinical point of view, the metabolomic analysis revealed
a different behavior that went beyond the clinical effects. Some of the
annotated metabolites suggest that a possible interaction between gut
microbiota and pidotimod could explain the role of the im-
munostimulant in preventing RRI. Future studies will be designed to
investigate that point.
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